Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for cognitive performance after ischemic stroke
IRCT20241125063842N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of escitalopram in ischemic stroke (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Cognitive performance status before and after intervention. Started Nov 2024; status: completed.
02
Drugs
escitalopram
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20241125063842N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241125063842N1.